Pregled bibliografske jedinice broj: 890811
Immunohistochemical expression of epidermal growth factor receptors, estrogen receptors beta, androgen receptors, MLH1, MSH6, PMS2, and MSH2 proteins in triple negative breast carcinoma
Immunohistochemical expression of epidermal growth factor receptors, estrogen receptors beta, androgen receptors, MLH1, MSH6, PMS2, and MSH2 proteins in triple negative breast carcinoma // Virchows Archiv. European Journal of Pathology. Supplement 1. Abstracts, 29th European Congress of Pathology / Massi, Daniela (ur.).
Amsterdam: Springer, 2017. str. S58-S59 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 890811 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Immunohistochemical expression of epidermal
growth factor receptors, estrogen receptors
beta, androgen receptors, MLH1, MSH6, PMS2, and
MSH2 proteins in triple negative breast
carcinoma
Autori
Dmitrovic, Branko ; Bakula, Marina ; Budiša, Ana ; Galić Krnjaić, Monika ; Mandić, Alisa
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Virchows Archiv. European Journal of Pathology. Supplement 1. Abstracts, 29th European Congress of Pathology
/ Massi, Daniela - Amsterdam : Springer, 2017, S58-S59
Skup
29th European Congress of Pathology. Pathology for Patient Care.
Mjesto i datum
Amsterdam, Nizozemska, 02.09.2017. - 06.09.2017
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Triple Negative Breast Cancer ; Epidermal Growth Factor Receptor ; Estrogen Receptor beta ; Androgen Receptor ; Microsatellite Instability
Sažetak
Objective: To compare the immunohistochemical expression of epidermal growth factor receptors (EGFR), estrogen receptors beta (ER-β), androgen receptors (AR), MLH1, MSH6, PMS2 and MSH2 proteins in tumor cells of the triple negative breast cancer and other breast cancers. Methods: The study was conducted on 30 samples of tumor tissue of patients diagnosed with triple negative breast cancer and 30 samples of tumor tissue of other breast cancers. Immunohistochemical expressions of EGFR, ER-β, AR, and MLH1, MSH6, PMS2, and MSH2 proteins were assessed semiquantitatively as 0 (negative), 1+ (up to 10% positive tumor cells), 2+ (11%- 30% positive tumor cells), 3+ (31% and more positive tumor cells). Relations with patients' age, tumor size, differentiation, HER2 amplification, Ki-67, and axillary lymph node status were calculated. Results: IHC expressions in the triple negative breast carcinoma group were: EGFR 36, 7%, ER-β 100%, AR 43, 3%, MLH1 100%, MSH6 100%, PMS2 100%, and MSH2 proteins 100%. There were no significant differences compared to the control group IHC expressions nor to the most other analyzed parameters. The lower the degree of the tumor differentiation/the higher the percentage of Ki-67 positive tumor cells, the rarer the expression of AR in tumor tissue is (p<0, 001). The expression of the MSH6 protein is associated with a significantly higher percentage of Ki-67 positive cells (p=0.001). The lower the degree of tumor differentiation, the higher is the expression of MSH6 (p=0.002). Conclusion: Triple negative breast carcinoma tissue positivity to the EGFR, ER-β, and AR points to a possible targets of hormonal or other aimed therapy in this group of breast cancer.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Napomena
Projekt VIF2016-MEFOS-21 Josip Juraj Strossmayer University of Osijek
POVEZANOST RADA
Projekti:
VIF2016-MEFOS-21
Ustanove:
Klinički bolnički centar Osijek,
Medicinski fakultet, Osijek,
Fakultet za dentalnu medicinu i zdravstvo, Osijek
Profili:
Branko Dmitrović
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE